Prognostic value of Muc5AC in gastric cancer: A meta-analysis

Table 1 Characteristics of the included studies

No.	Ref.	Year	Area	No. of patients	Gender M/F	Medium age	Therapy before surgical resection	Antibody used	Cut-off value	Purpose
1	Baldus et al[23]	2002	Germany	200	107/93	60.8	No	CLH2	35%	C/HR
2	Dae et al[25]	2013	South Korea	412	286/126	58.5	No	CLH2	10%	HR
3	Ilhan et al[24]	2010	Turkey	257	201/56	NR	No	45M1	5%	C
4	Kocer et al[16]	2004	Turkey	44	31/13	59.75	No	45M1	10%	C/HR
5	Lee et al[26]	2001	South Korea	300	203/97	NR	NR	CLH2	20%	C
6	Shiratsu et al[27]	2013	Japan	214	150/64	NR	No	CLH2	5%	C/HR
7	Suh et al[17]	2012	South Korea	450	328/122	57.5	No	NR	10%	HR
8	Sung et al[12]	2013	South Korea	412	286/126	58.5	No	CLH2	5%	C
9	Tajima et al[28]	2001	Japan	136	82/54	61.7	No	45M1	10%	C
10	Wang et al[18]	2003	China	76	52/24	65.0	NR	45M1	5%	C/HR
11	Wang et al[29]	2003	China	46	34/12	54.6	NR	45M1	0%	C

NR: Not reported; M: Male; F: Female; C: Clinicopathological characteristics; HR: Hazard ratio.

Table 2 Subgroup analysis of pooled hazard ratio in gastric cancer patients with decreased Muc5AC expression

	No. of studies	No. of patients	Pooled HR (95%CI)	Heterogeneity
				I2	P-value
Study location
East Asia	4	1152	1.39 (1.03-1.88)	33%	0.21
Non-East Asia	2	244	1.31 (0.92-1.86)	62%	0.10
Sample size
≥ 200	4	1276	1.34 (1.05-1.71)	0%	0.63
< 200	2	120	1.49 (0.76-2.94)	81%	0.02
Cut-off value
≥ 10%	4	1106	1.32 (1.03-1.7)	14%	0.32
< 10%	2	290	1.54 (0.87-2.71)	71%	0.06

Table 3 Meta-analysis of decreased Muc5AC expression and clinicopathological characteristics of gastric cancer

Clinicopathological characteristic	No. of studies	No. of patients	Pooled OR (95%CI)	Heterogeneity
				I2	P-value
TNM stage	4	801	1.15 (0.56-2.34), Random	78%	0.003
Tumor size	3	257	1.38 (0.84-2.28), Fixed	0%	0.83
Venous invasion	3	394	1.26 (0.82-1.94), Fixed	35%	0.21
Lymphatic invasion	3	650	1.27 (0.89-1.80), Fixed	25%	0.26